Dd-cfDNA as a prognostic biomarker for rejection - Data from the ProActive Study

July 12, 2023

Listen to Dr. Jonathan Bromberg, ProActive Study's lead Investigator, discuss how Prospera™ accurately predicted ABMR and TCMR before biopsy-proven rejection, up to 4 months and 2 months in advance respectively.

Dd-cfDNA as a prognostic biomarker for rejection - Data from the ProActive Study

Elevations of dd-cfDNA before bpAR ProActive Study Publication with Supplement April 2024

New Trifecta Study Publication: Prospera dd-cfDNA upheld as a leading indicator for kidney transplant rejection

Compassionate Care Application - Spanish

CEoT 2024 Flyer

ISHLT 2024 Flyer

What Nurses Need to Know: New data on implementing the Prospera™ donor-derived cell-free DNA test into your kidney transplant surveillance

Distinct Molecular Processes Mediate Donor-derived Cell-free DNA Release From Kidney Transplants in Different Disease States

Prospera Heart Explainer

Prospera Lung Explainer

Natera Product Brochure

Why Cell‐Free DNA Can Be a “Game Changer” for Lung Allograft Monitoring for Rejection and Infection

Letter to the Editors: Performance of Donor-derived Cell-free DNA Assays in Kidney Transplant Patients

Using both the Fraction and Quantity of Donor-Derived Cell-Free DNA to Detect Kidney Allograft Rejection

Single center experience comparing two clinically available donor derived cell free DNA tests and review of literature

Incorporation of Donor-derived Cell-free DNA Into Clinical Practice for Renal Allograft Management

Donor-derived Cell-free DNA Shows High Sensitivity for the Diagnosis of Pancreas Graft Rejection in Simultaneous Pancreas-kidney Transplanta

The Trifecta Study: Comparing Plasma Levels of Donor-derived Cell-Free DNA with the Molecular Phenotype of Kidney Transplant Biopsies

Real-world Clinical Experience Implementing Donor-derived Cell- free DNA for Detection of Acute Lung Allograft Dysfunction after Lung Trans

Prospera Patient Discussion Guide

Gigi talking about Prospera